125459

: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union.

This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects. 125459

: Defining scientific principles for non-clinical studies specifically for gene therapies, which differ significantly from conventional pharmaceuticals. Key Safety Requirements : : This guideline is a cornerstone for developers

: Checking if the patient might "shed" or spread the virus/vector through secretions. 125459

For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official .

: Assessing the risk of "insertional mutagenesis"—where the therapy might accidentally interfere with the patient's existing DNA.